
Injective (INJ) faces short-term recovery to $7.50 target despite current bearish momentum, with medium-term forecast eyeing $9.17 on Altria upgrade catalyst. (Read More)
Phone

Injective (INJ) faces short-term recovery to $7.50 target despite current bearish momentum, with medium-term forecast eyeing $9.17 on Altria upgrade catalyst. (Read More)